Business Update Positive

2026-08-26 16:46

- Mankind Pharma's Board on August 26, 2026, approved the voluntary liquidation of its 96% direct subsidiary, Bharat Serums and Vaccines Limited (BSVL). - The business of BSVL will be consolidated with Mankind Pharma on a going concern basis to drive operational efficiency and improved management.

Business Update Positive

2026-08-26 16:41

- Board Meeting on Aug 26, 2026, approved voluntary liquidation of 96% held subsidiary Bharat Serums and Vaccines Limited (BSVL). - BSVL's business will be integrated into Mankind Pharma for operational efficiency, business consolidation, and improved cash management.

Business Update Positive

2026-08-22 14:03

- Mankind Pharma's ESG Rating improved to 64 (Strong category) from 57 (Adequate category) by CRISIL ESG Ratings. - The Company's Core ESG Rating also improved to 71 from the previous rating of 60.

Business Update Positive

2026-08-20 13:39

- Mankind Pharma Limited entered an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd., China. - The agreement is for the commercialisation of Insulin Degludec and Insulin Degludec + Aspart Combination in India. - This partnership strengthens Mankind Pharma's presence in the diabetes segment and expands its injectable diabetes portfolio.

Governance Positive

2026-08-18 15:53

- Mankind Pharma Limited announces a postal ballot for the appointment of Mr. Anish Vanraj Bafna as a Non-Executive Independent Director for a term of five consecutive years. - E-voting period: August 19, 2026 (9:00 AM IST) to September 17, 2026 (5:00 PM IST). - Results will be declared on or before September 21, 2026. - Mr. Bafna brings over 30 years of experience in the healthcare and medical devices sector.

Ownership Positive

2026-08-17 23:11

- Mankind Pharma completed realignment of security cover for Non-Convertible Debentures (NCDs). - This resulted in the release of the pledge on 28,280 equity shares (38.68%) of Bharat Serums and Vaccines Limited (BSVL). - No shares of BSVL are now pledged for NCDs. - The revised security cover over tangible/intangible assets is 1.26 times the outstanding NCDs.

Business Update Positive

2026-08-13 21:32

- Mankind Pharma Limited incorporated its wholly-owned subsidiary, "Mankind Pharma (Netherlands) B.V.", in the Netherlands on August 13, 2026.

Governance Positive

2026-08-10 16:18

- The Board of Directors approved the appointment of Mr. Anish Vanraj Bafna as an Additional Director, designated as a Non-Executive Independent Director. - The appointment is effective from August 10, 2026, for a term of 5 consecutive years, subject to members' approval via Postal Ballot. - Mr. Bafna has over 30 years of experience in the healthcare and medical devices sector.

Governance Positive

2026-08-10 16:15

- Board approved the appointment of Mr. Anish Vanraj Bafna as an Additional Non-Executive Independent Director for 5 years, effective August 10, 2026, subject to shareholder approval. Mr. Bafna has over 30 years experience in healthcare.

Business Update Neutral

2026-08-10 12:44

- Mankind Pharma Limited will participate in investor conferences. - August 13, 2026: Emkay Confluence and Equirus Annual India Conference '26 in Mumbai. - August 17, 2026: Motilal Oswal 22nd Annual Global Investor Conference, 2026 in Mumbai. - No Unpublished Price Sensitive Information (UPSI) will be disclosed.

Governance Neutral

2026-08-04 17:35

- The 35th Annual General Meeting (AGM) of Mankind Pharma Limited was held on August 4, 2026, through video conferencing, concluding at 4:56 P.M. (IST). - Key agenda items included adopting the financial statements for FY 2025-26 and re-appointing Directors and cost auditors.

Business Update Positive

2026-08-04 13:16

- Consolidated Revenue ₹4,031Cr (▲13% YoY) - EBITDA ₹1,060Cr (EBITDA Margin 26.3%, ▲250bps YoY) - PAT ₹574Cr (▲29.1% YoY, PAT Margin 14.2%, ▲170bps YoY) - Gross margins increased to 72.8% (▲230bps YoY) - Domestic business revenue grew ▲10.5% YoY, driven by Chronic portfolio growth (▲15.8% YoY) and Acute portfolio recovery (▲10.9% YoY). - International business revenue grew ▲29% YoY. - Net debt reduced to ₹3,377Cr; on track to repay acquisition-related debt by FY28. - Maintained FY27 EBITDA guidance of 25.5% to 26.5% and gross margins upward of 71%. - Expects double-digit growth for the full year FY27, confident of progressively outperforming IPM. - Launched new division 'Vistar' and partnered for AI-led drug discovery; attrition has significantly dropped and is under control.

Routine Neutral

2026-07-30 20:32

New Filing detected. See link for details.

Financials Neutral

2026-07-30 16:03

CRITICAL RED FLAG DETECTED

- Standalone Revenue ₹2,964.05 Cr vs ₹2,569.73 Cr (▲15.34% YoY) - Standalone EBITDA ₹928.58 Cr vs ₹684.93 Cr (▲35.57% YoY) - Standalone PAT ₹558.49 Cr vs ₹415.27 Cr (▲34.49% YoY) - Standalone EBITDA Margin 31.39% vs 26.65% (▲474 bps) - Company noted pending income tax proceedings for adjustments aggregating to ~₹1,869 Cr, against which appeals have been filed.

Financials Positive

2026-07-30 15:55

- Consolidated Revenue ₹4,031Cr vs ₹3,570Cr (▲12.9% YoY) - EBITDA ₹1,060Cr vs ₹850Cr (▲24.7% YoY) - PAT ₹574Cr vs ₹445Cr (▲29.1% YoY) - EBITDA Margin 26.3% vs 23.8% (▲250bps)

Financials Positive

2026-07-30 15:34

CRITICAL RED FLAG DETECTED

- Unaudited Standalone Financial Results for Q1 FY27 (quarter ended June 30, 2026) were approved. Consolidated results table is not provided in this filing. - Standalone Operating Revenue ₹2,964.05 Cr vs ₹2,569.73 Cr (▲15.34% YoY) - Standalone EBITDA ₹928.58 Cr vs ₹684.93 Cr (▲35.57% YoY) - Standalone PAT ₹558.49 Cr vs ₹415.27 Cr (▲34.49% YoY) - Standalone EBITDA Margin 31.33% vs 26.65% (▲468bps) - The company's comparative unaudited standalone financial results for Q1 FY26 have been restated due to the acquisition of Bharat Serums and Vaccines Limited (BSV) for ₹797 crores. - Board approved issuance of a corporate guarantee in favour of Bharat Serums and Vaccines Limited (BSV), a wholly owned subsidiary. - The company divested 100% stake in Broadway Hospitality Services Private Limited for ₹49 crores. - **Red Flag**: Income tax proceedings initiated by the Income Tax Department from an earlier search are pending appeal, raising uncertainty.

Financials Positive

2026-07-30 15:24

- Consolidated Revenue ₹4,030.59Cr vs ₹3,570.35Cr (▲12.9% YoY) - EBITDA ₹1,060.13Cr vs ₹849.94Cr (▲24.7% YoY) - PAT ₹568.06Cr vs ₹438.32Cr (▲29.6% YoY) - EBITDA Margin 26.30% vs 23.81% (▲249bps) - Board approved a corporate guarantee of ₹150 crores for its wholly-owned subsidiary, Bharat Serums and Vaccines Limited. - The company divested its entire stake in Broadway Hospitality Services Private Limited for ₹49 crores (post-quarter end). - Noted ongoing income tax proceedings from FY23-24 with appeals filed against adjustments totaling ₹1,908.66 crores, with management asserting no material impact. - Recognized an impairment loss of ₹13.44 crores related to the suspension of a greenfield project in a subsidiary.

Business Update Positive

2026-07-27 18:32

- Mankind Pharma Limited completed the sale of its 100% stake in Broadway Hospitality Services Private Limited. - The transaction was executed on July 27, 2026, for a cash consideration of ₹49 Crore, subject to closing adjustments.

Business Update Neutral

2026-07-17 15:37

- Concall Schedule - Concall Date: Thursday, July 30, 2026 - Concall Time: 06:30 PM - 07:30 PM IST

Business Update Positive

2026-07-11 13:30

- Board approved divestment of 100% stake in Broadway Hospitality Services Private Limited for ₹49.00 Crores. This subsidiary contributed negligibly to company financials. - Also approved the incorporation of a wholly-owned subsidiary in Netherlands with a proposed investment of up to Euro 5 Million, for holding investments in R&D assets and business development activities focused on niche therapies.

Business Update Positive

2026-07-11 13:28

- Board of Directors approved the divestment of 100% stake in Broadway Hospitality Services Private Limited for ₹49.00 Crores. - Approved the incorporation of a wholly owned subsidiary in Netherlands to hold investments in R&D assets and develop niche therapies, with proposed investment up to Euro 5 Million.

Business Update Positive

2026-07-11 13:25

- Board approved divestment of 100% stake in Broadway Hospitality Services Private Limited for ₹49.00 Crores, expected to complete within 90 days. Broadway contributed negligibly to company financials. - Approved incorporation of a wholly-owned subsidiary in Netherlands for holding R&D investments and business development in niche therapies, with a proposed investment of up to Euro 5 Million.

Governance Neutral

2026-07-09 16:38

- Mankind Pharma Limited to hold its 35th AGM on August 4, 2026, at 3:30 PM (IST) via VC/OAVM. - Agenda includes adoption of FY25-26 financial statements, re-appointment of Mr. Rajeev Juneja and Mr. Satish Kumar Sharma, and ratification of cost auditors. - Remote e-voting from Aug 1 to Aug 3, 2026.

Governance Neutral

2026-06-30 11:56

- Intimation of the 35th Annual General Meeting (AGM) of Mankind Pharma Limited. - Scheduled for Tuesday, August 4, 2026, at 03:30 p.m. (IST). - To be held through Video Conferencing/Other Audio-Visual Means. - Notice of AGM and Annual Report for FY 2025-26 will be dispatched.

Routine Neutral

2026-06-25 12:31

- Trading window closed from July 01, 2026, for designated persons for the quarter ending June 30, 2026. - Reopening 48 hours after financial results declaration. - Board meeting date for results will be intimated later.

Business Update Neutral

2026-06-15 15:44

- Concall Schedule: Investor Conference - Concall Date: June 23 & 24, 2026 - Call Details: Mankind Pharma Limited management will participate in IIFL's Invest India Conference & Capital Day 2026 in London for one-on-one and group meetings. No unpublished price sensitive information will be shared.

Governance Neutral

2026-06-08 22:34

- Mankind Pharma Limited announced the appointment of Mr. Nilesh Kulkarni as Head of Human Resource Functions of the Group (designated as Senior Management Personnel - SMP) effective June 8, 2026. - This is part of an internal organizational restructuring. - Mr. Prateek Dubey ceased to be an SMP and will transition to new roles and responsibilities within the company.

Governance Neutral

2026-06-08 22:33

- Mankind Pharma appointed Mr. Nilesh Kulkarni as Head of Human Resource Functions (Senior Management Personnel). - The appointment is effective June 8, 2026, as part of an internal organizational restructuring. - Mr. Prateek Dubey ceased to be an SMP, transitioning to new roles and responsibilities within the company.

Routine Neutral

2026-06-08 18:15

- Mankind Pharma Limited allotted 86,778 equity shares on June 8, 2026, under its ESOP Plan 2022. - This allotment increases the paid-up share capital from 41,29,09,200 to 41,29,95,978 equity shares. - The newly allotted shares rank pari-passu with existing equity shares.

Business Update Positive

2026-06-02 17:47

- Mankind Pharma's WOS acquired the remaining 10% stake in Upakarma Ayurveda Private Limited for ₹75 Lakhs.- Upakarma, now a 100% WOS, deals in Ayurvedic, herbal, and nutraceutical products (2025-26 turnover: ₹18.02 Cr).- The acquisition, completed on June 2, 2026, aims for better operational efficiencies.

Business Update Neutral

2026-05-27 16:13

Mankind Pharma Limited announced that its management will participate in an Investor Conference organized by Bank of America on June 1, 2026, and hold meetings with various investors on June 2, 2026, in Mumbai. The company confirmed that no unpublished price sensitive information will be disclosed during these interactions, with discussions based on general business outlook and publicly available information.

Business Update Positive

2026-05-26 17:03

Management guided for FY27 to be a much better year with double-digit top-line growth, aiming to outperform IQVIA, driven by normalization in acute portfolio, sustained chronic therapy momentum, and increasing specialty/differentiated products including a recently launched GLP-1 pen. EBITDA margin is expected to be 25.5-26.5% for FY27 (vs 25.4% in FY26). International business is projected for high double-digit growth, reaching high teens to 20%. Capex for FY27 is guided at 6-7% of revenue, including a new biotech facility. The company is on track to repay acquisition-related debt by FY28, with the net debt to adjusted EBITDA ratio expected to reach 0.5x in FY27. The effective tax rate for FY27 is projected to increase to 25-26% due to the end of Sikkim exemption.

Business Update Neutral

2026-05-20 21:13

Mankind Pharma Limited announced that its management and officials will participate in investor meetings in Singapore on May 25-26, 2026. The discussions will be based on the general business outlook and information already in the public domain, with no unpublished price sensitive information being disclosed. The schedule for the investor conference is subject to change.

Business Update Neutral

2026-05-20 16:04

Mankind Pharma Limited informed about the availability of the audio recording for its Investor Conference Call for Q4 & FY26, which was held on May 20, 2026. The recording can be accessed on the company's website at https://www.mankindpharma.com/MankindPharma-Earnings-May20-2026.mp4.

Financials Positive

2026-05-19 20:11

Consolidated Revenue ₹3,443Cr vs ₹3,079Cr (▲11.8% YoY), Adjusted EBITDA ₹933Cr vs ₹711Cr (▲31.1% YoY), PAT ₹559Cr vs ₹429Cr (▲30.4% YoY). Adjusted EBITDA Margin 27.1% vs 23.1% (▲400bps).

Ownership Neutral

2026-05-19 19:29

Mankind Pharma Limited, on May 19, 2026, allotted 80,872 equity shares of ₹1/- face value to eligible employees under its ESOP Plan 2022. This increases the company's paid-up share capital from 41,28,28,328 to 41,29,09,200 Equity Shares. The shares rank pari-passu with existing shares. Exercise prices for these allotted shares range from ₹860.00 to ₹1,600.00 per share.

Financials Positive

2026-05-19 19:23

CRITICAL RED FLAG DETECTED

Mankind Pharma reported strong standalone financial results for Q4 FY26 with Revenue ₹2,581.82 Cr vs ₹2,119.46 Cr (▲21.89% YoY), EBITDA ₹896.02 Cr vs ₹341.84 Cr (▲162.15% YoY), and PAT ₹713.61 Cr vs ₹235.16 Cr (▲203.46% YoY). EBITDA Margin expanded significantly from 16% to 35% (▲1900bps). The Board also approved an additional investment of up to ₹500 crores in a wholly-owned subsidiary and noted that Executive Directors will not draw commission for FY2025-26 to strengthen cash for business expansion. However, the resignation of Mr. Pramod Gokhale, Global Chief Information Officer (KMP), was also noted.

Financials Negative

2026-05-19 19:20

CRITICAL RED FLAG DETECTED

Standalone Revenue ₹2,581.82 Cr vs ₹2,119.46 Cr (▲21.81% YoY), EBITDA ₹1,022.72 Cr vs ₹561.35 Cr (▲82.19% YoY), PAT ₹713.61 Cr vs ₹235.16 Cr (▲203.46% YoY). EBITDA Margin 39.61% vs 26.49% (▲1312 bps).

Financials Positive

2026-05-19 19:20

CRITICAL RED FLAG DETECTED

Mankind Pharma reported strong standalone Q4 FY26 results with Operating Revenue at ₹2,581.82 Cr vs ₹2,119.46 Cr (▲21.82% YoY), EBITDA at ₹896.02 Cr vs ₹341.84 Cr (▲162.1% YoY), and PAT at ₹713.61 Cr vs ₹235.16 Cr (▲203.46% YoY). EBITDA Margin expanded by 1857 bps to 34.70% from 16.13%. The board also approved an additional investment of up to ₹500 crores in a wholly-owned subsidiary and noted key executive directors foregoing commission for FY26 to strengthen cash. However, Mr. Pramod Gokhale (Global CIO) resigned, and auditors highlighted ongoing income tax proceedings regarding ₹1,868.89 crores in adjustments for previous years.

Financials Neutral

2026-05-19 19:16

CRITICAL RED FLAG DETECTED

Standalone Revenue ₹2,581.82 Cr vs ₹2,119.46 Cr (▲21.89% YoY), EBITDA ₹903.64 Cr vs ₹339.11 Cr (▲166.47% YoY), PAT ₹713.61 Cr vs ₹235.16 Cr (▲203.46% YoY). EBITDA Margin 35% vs 16% (▲1900 bps). The company also approved the re-appointment of a Whole-Time Director and Cost Auditors, realignment of NCD security cover post ₹1,250 Cr redemption, and an additional investment of up to ₹500 Cr in a subsidiary. Executive Directors will not draw commission for FY26 to strengthen cash position.

Financials Positive

2026-05-19 19:16

CRITICAL RED FLAG DETECTED

Mankind Pharma Limited reported strong Q4 FY26 consolidated financial results. Consolidated Revenue from operations stood at ₹3,442.93 Cr vs ₹3,079.37 Cr (▲11.79% YoY), EBITDA was ₹909.71 Cr vs ₹685.51 Cr (▲32.70% YoY), and PAT (attributable to equity holders of parent) was ₹554.35 Cr vs ₹425.11 Cr (▲30.40% YoY). EBITDA Margin expanded to 26.42% vs 22.26% (▲416 bps). The Board also approved the realignment of security cover for NCDs post redemption of ₹1,250 Cr, additional investment of ₹500 Cr in a subsidiary, and the re-appointment of a Whole-Time Director and Cost Auditors. Executive Directors decided not to draw commission for FY26 to strengthen cash for business expansion.

Routine Positive

2026-05-12 18:46

Mankind Pharma Limited announced that ICRA Limited reaffirmed credit ratings for its Long-term/Short term fund based limits (₹1,250 crore) at [ICRA]AA+ (Stable)/[ICRA]A1+ and Non-convertible Debentures (₹5,000 crore) at [ICRA]AA+ (Stable). Additionally, a new rating of [ICRA]A1+ was assigned to its Commercial Paper (₹600 crore).

Business Update Neutral

2026-05-08 19:29

Mankind Pharma Limited announced an Investor Conference Call on May 20, 2026, at 12:00 PM IST, to discuss the company's Q4FY26 and full-year FY26 business performance and results. Senior management, including the Vice Chairman & Managing Director and CEO, will participate in the call.

Routine Neutral

2026-04-22 20:47

New Filing detected. See link for details.

Business Update Neutral

2026-04-13 15:29

The Board approved the closure/winding-up of Mankind Pharma Lanka (Private) Limited, a wholly-owned subsidiary in Sri Lanka, due to changed regulatory requirements making business objectives unviable. The subsidiary had no business operations and is not considered material.

Business Update Neutral

2026-04-13 15:26

Mankind Pharma's Board approved the closure/winding-up of its wholly-owned subsidiary, Mankind Pharma Lanka (Private) Limited in Sri Lanka, due to changed regulatory requirements making business objectives unviable. The subsidiary had no business operations and is not a material subsidiary.

Routine Neutral

2026-04-06 15:19

Mankind Pharma Limited submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming no requests for dematerialisation/rematerialisation of shares were received for the quarter ended March 31, 2026.

Business Update Positive

2026-03-18 10:02

Mankind Pharma announced on March 18, 2026, the acquisition of the Rivotril brand from Roche for India. This strategic move strengthens the company's focus on chronic Central Nervous System (CNS) therapies and expands its neuro portfolio.

Ownership Positive

2026-03-16 13:45

Mankind Pharma Limited on March 16, 2026, allotted 23,256 equity shares under its ESOP Plan 2022 at an exercise price of ₹860 per share. This increased the paid-up share capital from 41,28,05,072 to 41,28,28,328 equity shares.

Business Update Positive

2026-02-26 18:27

Mankind Pharma announced that an appeal against an earlier order resulted in the dropping of a penalty of INR 1,02,05,688/- (approximately ₹1.02 Crore) under the CGST Act, 2017, for the financial years 2017-21.

Business Update Positive

2026-02-24 18:22

ICRA Limited has reaffirmed the Credit Ratings for Mankind Pharma Limited's Non-Convertible Debentures at (ICRA) AA+/Stable and Long-term/Short-term fund-based limits at (ICRA)AA+(Stable)/(ICRA)A1+ on February 24, 2026.

Business Update Neutral

2026-02-18 15:07

Mankind Pharma Limited will participate in the 'Chasing Growth 2026' Investor Conference in Mumbai on February 24, 2026. The meeting will involve one-on-one and group discussions. No unpublished price sensitive information will be shared at the conference.

Business Update Positive

2026-02-16 18:51

Mankind Pharma announced that the Joint Commissioner of State Tax, Nagpur, has issued an order dated February 16, 2026, dropping the penalty of INR 46,32,582/- related to a GST matter for FY2020-21, following the company's appeal against a previous order.

Business Update Negative

2026-02-09 15:04

CRITICAL RED FLAG DETECTED

Mankind Pharma disclosed a GST Department search/inspection at its unlisted subsidiary, Bharat Serums and Vaccines Limited, from February 3-8, 2026, relating to tax payments and input tax credit. The company stated operations continued as usual with no material impact.

Financials Positive

2026-02-09 13:42

Overall Revenue was INR 3,567 crores in Q3 FY26 compared to INR 3,199 crores in Q3 FY25, marking an 11.5% YoY increase. The adjusted EBITDA margin for Q3 FY26 was 25.9%.

Business Update Neutral

2026-02-04 13:56

Mankind Pharma Limited will participate in the MANTHAN – Systematix India Annual Flagship Conference on February 9, 2026, and the Advantage India - Axis Capital's Flagship India Conference on February 10, 2026, both in Mumbai. These will involve one-on-one and group meetings, with no unpublished price sensitive information being shared.

Routine Neutral

2026-02-03 22:04

New Filing detected. See link for details.

Financials Neutral

2026-02-03 16:31

CRITICAL RED FLAG DETECTED

Mankind Pharma's Board approved unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025. The auditor's review report includes an emphasis of matter regarding pending income tax proceedings from an earlier year.

Financials Positive

2026-02-03 16:28

Consolidated Revenue ₹3,567Cr vs ₹3,199Cr (▲11.5% YoY), EBITDA ₹816Cr vs ₹819Cr (▼0.4% YoY). EBITDA Margin 22.9% vs 25.6% (▼270bps).

Financials Positive

2026-02-03 16:23

Consolidated Revenue ₹3,567Cr vs ₹3,199Cr (▲11.5% YoY), Adjusted EBITDA ₹923Cr vs ₹883Cr (▲4.6% YoY), PAT ₹414Cr vs ₹378Cr (▲9.5% YoY). Adjusted EBITDA Margin 25.9% vs 27.6% (▼170bps).

Financials Negative

2026-02-03 16:16

CRITICAL RED FLAG DETECTED

Mankind Pharma's Board approved standalone and consolidated financial results for the quarter ended December 31, 2025. A red flag is noted due to ongoing income tax proceedings, with disallowances totaling ₹1,825.66 Cr. The company has appealed these adjustments, stating no material impact on financials is expected.

MANKIND

Mankind Pharma Limited

Price Chart

Filing History

Unlock Full History